In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

Analysts covering EyePoint have refreshed their models, with bullish price targets now clustered in the US$29 to US$35 range. These revisions are being linked to more detailed valuation work on the ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth ...

The U.S. burden of blinding retinal conditions is high, according to a meta-analysis published online March 19 in JAMA ...

Japan MHLW grants marketing authorization to Bayer’s Eylea 8 mg to treat patients with macular edema following RVO: Berlin Tuesday, March 24, 2026, 13:00 Hrs [IST] The Ministry ...

A pair of rivals developing drugs for common retinal diseases are not seeing eye to eye. | A pair of rivals developing drugs for common retinal diseases are not seeing eye to eye. EyePoint on Friday ...

Researchers also suggest potential new genetic associations with macular edema, which warrant further research. A study published in Scientific Reports confirmed previously identified retinal ...

Brolucizumab (Beovu) proved noninferior to aflibercept (Eylea) for visual outcomes among patients with diabetic macular edema (DME), the phase III KINGFISHER trial showed. In over 500 patients with ...

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.